|Ms. Kristina Hachey||CFO & Director||N/A||N/A||N/A|
|Dr. Arkady Mandel||Chief Scientific Officer & Director||N/A||N/A||N/A|
|Mr. Roger John Dumoulin-White||Director of Bus. Devel.||N/A||N/A||N/A|
|Dr. Shawn Shirazi Ph.D.||Chief Exec. Officer||N/A||N/A||N/A|
|Mr. David M. Groves B.A||Pres of World Trade Division||N/A||N/A||N/A|
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Anti-Cancer Therapy and Medical Laser Technology. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.
Theralase Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.